Entering text into the input field will update the search result below

SELB Selecta Biosciences, Inc.
Stock Price & Overview

$1.140.03 (+2.70%)4:00 PM 09/27/23
NASDAQ | $USD | Post-Market: $1.13 -0.01 (-0.79%) 6:25 PM


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

Ratings Summary

Now6M ago
SA Analysts
Not CoveredRating: Not Covered
Wall Street
Not CoveredRating: Not Covered
Not CoveredRating: Not Covered

Ratings Summary

SA Analysts
Wall Street
Now3M ago6M ago
-Rating: Not Covered
-Rating: Not Covered
-Rating: Not Covered
-Rating: Not Covered
-Rating: Not Covered

See SELB ratings with Premium.

Company Profile

Selecta Biosciences, Inc. logo
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company’s lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
  • 65 Grove Street
  • Watertown, MA, 02472
  • United States
Phone Number
617 923 1400
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.